137 related articles for article (PubMed ID: 18717740)
21. Laboratory diagnosis and molecular basis of mild von Willebrand disease type 1.
Michiels JJ; Berneman Z; Gadisseur A; van der Planken M; Schroyens W; van Vliet HH
Acta Haematol; 2009; 121(2-3):85-97. PubMed ID: 19506353
[TBL] [Abstract][Full Text] [Related]
22. Improved visualisation of high-molecular-weight von Willebrand factor multimers.
John Bowen D; Bowley SJ
Thromb Haemost; 2007 Jun; 97(6):1051-2. PubMed ID: 17549311
[No Abstract] [Full Text] [Related]
23. Desmopressin therapy to assist the functional identification and characterisation of von Willebrand disease: differential utility from combining two (VWF:CB and VWF:RCo) von Willebrand factor activity assays?
Favaloro EJ; Thom J; Patterson D; Just S; Dixon T; Koutts J; Baccala M; Rowell J; Baker R
Thromb Res; 2009 Apr; 123(6):862-8. PubMed ID: 19064279
[TBL] [Abstract][Full Text] [Related]
24. [Inborn and acquired von Willebrand disease].
Schneppenheim R; Budde U
Hamostaseologie; 2008 Dec; 28(5):312-9. PubMed ID: 19132162
[TBL] [Abstract][Full Text] [Related]
25. Prophylaxis in von Willebrand disease.
Berntorp E
Haemophilia; 2008 Nov; 14 Suppl 5():47-53. PubMed ID: 18786010
[TBL] [Abstract][Full Text] [Related]
26. von Willebrand factor: factor VIII protector and friend.
Ragni MV
J Thromb Haemost; 2012 Nov; 10(11):2324-7. PubMed ID: 22974054
[No Abstract] [Full Text] [Related]
27. Components and assembly of the factor X activating complex.
Ahmad SS; Rawala-Sheikh R; Walsh PN
Semin Thromb Hemost; 1992; 18(3):311-23. PubMed ID: 1455249
[No Abstract] [Full Text] [Related]
28. PFA-100 monitoring of von Willebrand factor (VWF) responses to desmopressin (DDAVP) and factor VIII/VWF concentrate substitution in von Willebrand disease type 1 and 2.
van Vliet HH; Kappers-Klunne MC; Leebeek FW; Michiels JJ
Thromb Haemost; 2008 Sep; 100(3):462-8. PubMed ID: 18766263
[TBL] [Abstract][Full Text] [Related]
29. Acquired von Willebrand syndrome.
Alvarez MT; Jimenez-Yuste V; Gracia J; Quintana M; Hernandez-Navarro F
Haemophilia; 2008 Jul; 14(4):856-8. PubMed ID: 18445010
[No Abstract] [Full Text] [Related]
30. Diagnosis of von Willebrand disease subtypes: implications for treatment.
Budde U
Haemophilia; 2008 Nov; 14 Suppl 5():27-38. PubMed ID: 18786008
[TBL] [Abstract][Full Text] [Related]
31. Big piece, little piece or: yes, factor VIII is a protein.
Owen WG
J Thromb Haemost; 2005 Sep; 3(9):1905-9. PubMed ID: 16102092
[No Abstract] [Full Text] [Related]
32. Successful surgical hemostasis in patients with von Willebrand disease following infusion of KoateDVI.
Srivastava A; Mathews V; Bhurani D; Baidya S; Chandy M
Thromb Haemost; 2002 Mar; 87(3):541-3. PubMed ID: 11916092
[No Abstract] [Full Text] [Related]
33. von Willebrand factor protects the Ca2+-dependent structure of the factor VIII light chain.
Takeyama M; Nogami K; Okuda M; Shima M
Br J Haematol; 2009 Sep; 146(5):531-7. PubMed ID: 19594746
[TBL] [Abstract][Full Text] [Related]
34. Preventing excessive bleeding in patients with von Willebrand disease.
Gill JC
Clin Adv Hematol Oncol; 2006 Mar; 4(3):207-9. PubMed ID: 16728929
[No Abstract] [Full Text] [Related]
35. Cold-dependent loss of factor VIII von Willebrand factor activities in citrated whole blood is reversed by rewarming.
Refaai MA; Lukoszyk M; Hughes J; Eby CS; Van Cott EM
Am J Clin Pathol; 2005 Dec; 124(6):972; author reply 973. PubMed ID: 16416745
[No Abstract] [Full Text] [Related]
36. [Urgent hemostatic control with Confact F for ovarian bleeding complicated by an unknown type of von Willebrand disease].
Suzuki T; Kagawa K; Oishi T; Kawata K; Fujito A; Isaka K; Fukutake K
Rinsho Ketsueki; 2008 Dec; 49(12):1623-7. PubMed ID: 19110525
[TBL] [Abstract][Full Text] [Related]
37. Toward a new paradigm for the identification and functional characterization of von Willebrand disease.
Favaloro EJ
Semin Thromb Hemost; 2009 Feb; 35(1):60-75. PubMed ID: 19308894
[TBL] [Abstract][Full Text] [Related]
38. The effects of flow on blood coagulation and thrombosis.
Slack SM; Cui Y; Turitto VT
Thromb Haemost; 1993 Jul; 70(1):129-34. PubMed ID: 8236088
[No Abstract] [Full Text] [Related]
39. Laboratory and molecular characteristics of recessive von Willebrand disease type 2C (2A subtype IIC) of variable severity due to homozygous or double heterozygous mutations in the D1 and D2 domains.
Michiels JJ; Gadisseur A; van der Planken M; Schroyens W; Berneman Z
Acta Haematol; 2009; 121(2-3):111-8. PubMed ID: 19506357
[TBL] [Abstract][Full Text] [Related]
40. The vWF content of factor VIII concentrates.
Agrawal YP; Dzik W
Transfusion; 2001 Jan; 41(1):153-4. PubMed ID: 11161262
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
